Search company, investor...

Marcadia Biotech

marcadiabiotech.com

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$16M

Valuation

$0000 

About Marcadia Biotech

Marcadia Biotech is developing pipeline of peptide therapeutics to treat metabolic disease

Headquarters Location

11711 North Meridian Street Suite 300

Carmel, Indiana, 46032,

United States

317-566-2266

Missing: Marcadia Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Marcadia Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Marcadia Biotech Patents

Marcadia Biotech has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/10/2011

9/29/2015

G protein coupled receptors, Olfactory receptors, Autosomal recessive disorders, Rare diseases, Diabetes

Grant

Application Date

5/10/2011

Grant Date

9/29/2015

Title

Related Topics

G protein coupled receptors, Olfactory receptors, Autosomal recessive disorders, Rare diseases, Diabetes

Status

Grant

Latest Marcadia Biotech News

MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases

Jul 27, 2020

Financing led by Frazier Healthcare Partners with Participation from OrbiMed and New Enterprise Associates July 27, 2020 08:00 AM Eastern Daylight Time CARMEL, Ind.--( BUSINESS WIRE )--MBX Biosciences, a drug discovery company focused in rare endocrine diseases, today announced the closing of a $34.6 million Series A financing. The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II. Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX. The company seeks to address rare endocrine disorders with substantial unmet medical need. “With the support of these leading life science investors, we are equipped to advance our drug candidates toward clinical investigation in underserved disease areas,” said Kent Hawryluk, president and chief executive officer of MBX. “We are excited to assemble a team with a proven track record in discovering and developing novel drugs to address unmet medical needs.” In conjunction with the financing, MBX has appointed three new members to its board of directors : Patrick Heron, managing partner of Frazier Healthcare Partners; Carl Gordon, Ph.D., managing partner of OrbiMed; and Ed Mathers, general partner of New Enterprise Associates. They join Mr. Hawryluk and Dr. DiMarchi. “Following the successful history of Marcadia Biotech and Calibrium with Richard and Kent, Frazier is proud to fund the next stage of MBX’s development,” said Mr. Heron. “Together with OrbiMed and NEA, we look forward to helping build another world-class drug development company in Indianapolis with this leadership team.” About MBX Biosciences MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX’s leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. The company is supported by investment from leading life science investors that include Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates. For more information, please visit mbxbio.com .

Marcadia Biotech Frequently Asked Questions (FAQ)

  • When was Marcadia Biotech founded?

    Marcadia Biotech was founded in 2005.

  • Where is Marcadia Biotech's headquarters?

    Marcadia Biotech's headquarters is located at 11711 North Meridian Street, Carmel.

  • What is Marcadia Biotech's latest funding round?

    Marcadia Biotech's latest funding round is Acquired.

  • How much did Marcadia Biotech raise?

    Marcadia Biotech raised a total of $16M.

  • Who are the investors of Marcadia Biotech?

    Investors of Marcadia Biotech include Roche Holding, 5AM Ventures, Twilight Venture Partners and Frazier Healthcare Partners.

  • Who are Marcadia Biotech's competitors?

    Competitors of Marcadia Biotech include Humanetics, Intarcia Therapeutics, Gamida Cell, Rhythm Pharmaceuticals, Cerenis Therapeutics and 12 more.

Compare Marcadia Biotech to Competitors

D
DermaGen

DermaGen develops peptide therapeutics for topical use based on antimicrobial peptides (AMPs).

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

M
Marval Biosciences

Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.

C
Cosmo S.p.A.

Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.